PubMed:15859361 JSON TXT

Annnotations TAB JSON ListView MergeView

LitCoin-sentences

{"project":"LitCoin-sentences","denotations":[{"id":"T1","span":{"begin":0,"end":174},"obj":"Sentence"},{"id":"T2","span":{"begin":175,"end":186},"obj":"Sentence"},{"id":"T3","span":{"begin":187,"end":299},"obj":"Sentence"},{"id":"T4","span":{"begin":300,"end":380},"obj":"Sentence"},{"id":"T5","span":{"begin":381,"end":484},"obj":"Sentence"},{"id":"T6","span":{"begin":485,"end":569},"obj":"Sentence"},{"id":"T7","span":{"begin":570,"end":580},"obj":"Sentence"},{"id":"T8","span":{"begin":581,"end":742},"obj":"Sentence"},{"id":"T9","span":{"begin":743,"end":751},"obj":"Sentence"},{"id":"T10","span":{"begin":752,"end":862},"obj":"Sentence"},{"id":"T11","span":{"begin":863,"end":939},"obj":"Sentence"},{"id":"T12","span":{"begin":940,"end":1012},"obj":"Sentence"},{"id":"T13","span":{"begin":1013,"end":1097},"obj":"Sentence"},{"id":"T14","span":{"begin":1098,"end":1155},"obj":"Sentence"},{"id":"T15","span":{"begin":1156,"end":1282},"obj":"Sentence"},{"id":"T16","span":{"begin":1283,"end":1402},"obj":"Sentence"},{"id":"T17","span":{"begin":1403,"end":1411},"obj":"Sentence"},{"id":"T18","span":{"begin":1412,"end":1490},"obj":"Sentence"},{"id":"T19","span":{"begin":1491,"end":1552},"obj":"Sentence"},{"id":"T20","span":{"begin":1553,"end":1564},"obj":"Sentence"},{"id":"T21","span":{"begin":1565,"end":1671},"obj":"Sentence"},{"id":"T22","span":{"begin":1672,"end":1782},"obj":"Sentence"}],"text":"Safety of celecoxib in patients with adverse skin reactions to acetaminophen (paracetamol) and nimesulide associated or not with common non-steroidal anti-inflammatory drugs.\nBACKGROUND: Acetaminophen (paracetamol--P) and Nimesulide (N) are widely used analgesic-antipyretic/anti-inflammatory drugs. The rate of adverse hypersensitivity reactions to these agents is generally low. On the contrary non-steroidal anti-inflammatory drugs (NSAIDs) are commonly involved in such reactions. Celecoxib (CE) is a novel drug, with high selectivity and affinity for COX-2 enzyme.\nOBJECTIVE: We evaluated the tolerability of CE in a group of patients with documented history of adverse cutaneous reactions to P and N associated or not to classic NSAIDs.\nMETHODS: We studied 9 patients with hypersensitivity to P and N with or without associated reactions to classic NSAIDs. The diagnosis of P and N-induced skin reactions was based in vivo challenge. The placebo was blindly administered at the beginning of each challenge. After three days, a cumulative dosage of 200 mg of CE in refracted doses were given. After 2-3 days, a single dose of 200 mg was administered. All patients were observed for 6 hours after each challenge, and controlled again after 24 hours to exclude delayed reactions. The challenge was considered positive if one or more of the following appeared: erythema, rush or urticaria-angioedema.\nRESULTS: No reaction was observed with placebo and eight patients (88.8%) tolerated CE. Only one patient developed a moderate angioedema of the lips.\nCONCLUSION: Only one hypersensitivity reaction to CE was documented among 9 P and N-highly NSAIDs intolerant patients. Thus, we conclude that CE is a reasonably safe alternative to be used in subjects who do not tolerate P and N."}

LitCoin-entities

LitCoin_Mondo

{"project":"LitCoin_Mondo","denotations":[{"id":"T1","span":{"begin":1381,"end":1390},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T2","span":{"begin":1391,"end":1401},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3","span":{"begin":1529,"end":1539},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"0005492"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"0010481"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"0010481"}],"text":"Safety of celecoxib in patients with adverse skin reactions to acetaminophen (paracetamol) and nimesulide associated or not with common non-steroidal anti-inflammatory drugs.\nBACKGROUND: Acetaminophen (paracetamol--P) and Nimesulide (N) are widely used analgesic-antipyretic/anti-inflammatory drugs. The rate of adverse hypersensitivity reactions to these agents is generally low. On the contrary non-steroidal anti-inflammatory drugs (NSAIDs) are commonly involved in such reactions. Celecoxib (CE) is a novel drug, with high selectivity and affinity for COX-2 enzyme.\nOBJECTIVE: We evaluated the tolerability of CE in a group of patients with documented history of adverse cutaneous reactions to P and N associated or not to classic NSAIDs.\nMETHODS: We studied 9 patients with hypersensitivity to P and N with or without associated reactions to classic NSAIDs. The diagnosis of P and N-induced skin reactions was based in vivo challenge. The placebo was blindly administered at the beginning of each challenge. After three days, a cumulative dosage of 200 mg of CE in refracted doses were given. After 2-3 days, a single dose of 200 mg was administered. All patients were observed for 6 hours after each challenge, and controlled again after 24 hours to exclude delayed reactions. The challenge was considered positive if one or more of the following appeared: erythema, rush or urticaria-angioedema.\nRESULTS: No reaction was observed with placebo and eight patients (88.8%) tolerated CE. Only one patient developed a moderate angioedema of the lips.\nCONCLUSION: Only one hypersensitivity reaction to CE was documented among 9 P and N-highly NSAIDs intolerant patients. Thus, we conclude that CE is a reasonably safe alternative to be used in subjects who do not tolerate P and N."}

LitCoin-GeneOrGeneProduct-v0

{"project":"LitCoin-GeneOrGeneProduct-v0","denotations":[{"id":"T1","span":{"begin":45,"end":49},"obj":"GeneOrGeneProduct"},{"id":"T2","span":{"begin":320,"end":336},"obj":"GeneOrGeneProduct"},{"id":"T3","span":{"begin":505,"end":510},"obj":"GeneOrGeneProduct"},{"id":"T4","span":{"begin":522,"end":526},"obj":"GeneOrGeneProduct"},{"id":"T5","span":{"begin":556,"end":561},"obj":"GeneOrGeneProduct"},{"id":"T6","span":{"begin":562,"end":568},"obj":"GeneOrGeneProduct"},{"id":"T7","span":{"begin":598,"end":610},"obj":"GeneOrGeneProduct"},{"id":"T8","span":{"begin":617,"end":621},"obj":"GeneOrGeneProduct"},{"id":"T9","span":{"begin":743,"end":750},"obj":"GeneOrGeneProduct"},{"id":"T10","span":{"begin":779,"end":795},"obj":"GeneOrGeneProduct"},{"id":"T11","span":{"begin":888,"end":895},"obj":"GeneOrGeneProduct"},{"id":"T12","span":{"begin":896,"end":900},"obj":"GeneOrGeneProduct"},{"id":"T13","span":{"begin":915,"end":920},"obj":"GeneOrGeneProduct"},{"id":"T14","span":{"begin":956,"end":963},"obj":"GeneOrGeneProduct"},{"id":"T15","span":{"begin":984,"end":993},"obj":"GeneOrGeneProduct"},{"id":"T16","span":{"begin":1058,"end":1060},"obj":"GeneOrGeneProduct"},{"id":"T17","span":{"begin":1135,"end":1137},"obj":"GeneOrGeneProduct"},{"id":"T18","span":{"begin":1156,"end":1159},"obj":"GeneOrGeneProduct"},{"id":"T19","span":{"begin":1373,"end":1377},"obj":"GeneOrGeneProduct"},{"id":"T20","span":{"begin":1477,"end":1486},"obj":"GeneOrGeneProduct"},{"id":"T21","span":{"begin":1547,"end":1551},"obj":"GeneOrGeneProduct"},{"id":"T22","span":{"begin":1574,"end":1590},"obj":"GeneOrGeneProduct"},{"id":"T23","span":{"begin":1637,"end":1643},"obj":"GeneOrGeneProduct"},{"id":"T24","span":{"begin":1765,"end":1773},"obj":"GeneOrGeneProduct"}],"text":"Safety of celecoxib in patients with adverse skin reactions to acetaminophen (paracetamol) and nimesulide associated or not with common non-steroidal anti-inflammatory drugs.\nBACKGROUND: Acetaminophen (paracetamol--P) and Nimesulide (N) are widely used analgesic-antipyretic/anti-inflammatory drugs. The rate of adverse hypersensitivity reactions to these agents is generally low. On the contrary non-steroidal anti-inflammatory drugs (NSAIDs) are commonly involved in such reactions. Celecoxib (CE) is a novel drug, with high selectivity and affinity for COX-2 enzyme.\nOBJECTIVE: We evaluated the tolerability of CE in a group of patients with documented history of adverse cutaneous reactions to P and N associated or not to classic NSAIDs.\nMETHODS: We studied 9 patients with hypersensitivity to P and N with or without associated reactions to classic NSAIDs. The diagnosis of P and N-induced skin reactions was based in vivo challenge. The placebo was blindly administered at the beginning of each challenge. After three days, a cumulative dosage of 200 mg of CE in refracted doses were given. After 2-3 days, a single dose of 200 mg was administered. All patients were observed for 6 hours after each challenge, and controlled again after 24 hours to exclude delayed reactions. The challenge was considered positive if one or more of the following appeared: erythema, rush or urticaria-angioedema.\nRESULTS: No reaction was observed with placebo and eight patients (88.8%) tolerated CE. Only one patient developed a moderate angioedema of the lips.\nCONCLUSION: Only one hypersensitivity reaction to CE was documented among 9 P and N-highly NSAIDs intolerant patients. Thus, we conclude that CE is a reasonably safe alternative to be used in subjects who do not tolerate P and N."}

LitCoin-GeneOrGeneProduct-v2

{"project":"LitCoin-GeneOrGeneProduct-v2","denotations":[{"id":"T1","span":{"begin":505,"end":510},"obj":"GeneOrGeneProduct"},{"id":"T2","span":{"begin":522,"end":526},"obj":"GeneOrGeneProduct"},{"id":"T3","span":{"begin":556,"end":561},"obj":"GeneOrGeneProduct"},{"id":"T4","span":{"begin":562,"end":568},"obj":"GeneOrGeneProduct"},{"id":"T5","span":{"begin":1373,"end":1377},"obj":"GeneOrGeneProduct"},{"id":"T6","span":{"begin":1547,"end":1551},"obj":"GeneOrGeneProduct"}],"text":"Safety of celecoxib in patients with adverse skin reactions to acetaminophen (paracetamol) and nimesulide associated or not with common non-steroidal anti-inflammatory drugs.\nBACKGROUND: Acetaminophen (paracetamol--P) and Nimesulide (N) are widely used analgesic-antipyretic/anti-inflammatory drugs. The rate of adverse hypersensitivity reactions to these agents is generally low. On the contrary non-steroidal anti-inflammatory drugs (NSAIDs) are commonly involved in such reactions. Celecoxib (CE) is a novel drug, with high selectivity and affinity for COX-2 enzyme.\nOBJECTIVE: We evaluated the tolerability of CE in a group of patients with documented history of adverse cutaneous reactions to P and N associated or not to classic NSAIDs.\nMETHODS: We studied 9 patients with hypersensitivity to P and N with or without associated reactions to classic NSAIDs. The diagnosis of P and N-induced skin reactions was based in vivo challenge. The placebo was blindly administered at the beginning of each challenge. After three days, a cumulative dosage of 200 mg of CE in refracted doses were given. After 2-3 days, a single dose of 200 mg was administered. All patients were observed for 6 hours after each challenge, and controlled again after 24 hours to exclude delayed reactions. The challenge was considered positive if one or more of the following appeared: erythema, rush or urticaria-angioedema.\nRESULTS: No reaction was observed with placebo and eight patients (88.8%) tolerated CE. Only one patient developed a moderate angioedema of the lips.\nCONCLUSION: Only one hypersensitivity reaction to CE was documented among 9 P and N-highly NSAIDs intolerant patients. Thus, we conclude that CE is a reasonably safe alternative to be used in subjects who do not tolerate P and N."}

LitCoin-Disease-MeSH

{"project":"LitCoin-Disease-MeSH","denotations":[{"id":"T1","span":{"begin":155,"end":167},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T2","span":{"begin":280,"end":292},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3","span":{"begin":320,"end":336},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T4","span":{"begin":416,"end":428},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T5","span":{"begin":779,"end":795},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T6","span":{"begin":1363,"end":1371},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T7","span":{"begin":1381,"end":1390},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T8","span":{"begin":1391,"end":1401},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T9","span":{"begin":1529,"end":1539},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T10","span":{"begin":1574,"end":1590},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A4","pred":"originalLabel","subj":"T4","obj":"DISEASE"},{"id":"A10","pred":"originalLabel","subj":"T10","obj":"D006967"},{"id":"A5","pred":"originalLabel","subj":"T5","obj":"D006967"},{"id":"A6","pred":"originalLabel","subj":"T6","obj":"D004890"},{"id":"A7","pred":"originalLabel","subj":"T7","obj":"D014581"},{"id":"A8","pred":"originalLabel","subj":"T8","obj":"D000799"},{"id":"A2","pred":"originalLabel","subj":"T2","obj":"DISEASE"},{"id":"A1","pred":"originalLabel","subj":"T1","obj":"DISEASE"},{"id":"A9","pred":"originalLabel","subj":"T9","obj":"D000799"},{"id":"A3","pred":"originalLabel","subj":"T3","obj":"D006967"}],"text":"Safety of celecoxib in patients with adverse skin reactions to acetaminophen (paracetamol) and nimesulide associated or not with common non-steroidal anti-inflammatory drugs.\nBACKGROUND: Acetaminophen (paracetamol--P) and Nimesulide (N) are widely used analgesic-antipyretic/anti-inflammatory drugs. The rate of adverse hypersensitivity reactions to these agents is generally low. On the contrary non-steroidal anti-inflammatory drugs (NSAIDs) are commonly involved in such reactions. Celecoxib (CE) is a novel drug, with high selectivity and affinity for COX-2 enzyme.\nOBJECTIVE: We evaluated the tolerability of CE in a group of patients with documented history of adverse cutaneous reactions to P and N associated or not to classic NSAIDs.\nMETHODS: We studied 9 patients with hypersensitivity to P and N with or without associated reactions to classic NSAIDs. The diagnosis of P and N-induced skin reactions was based in vivo challenge. The placebo was blindly administered at the beginning of each challenge. After three days, a cumulative dosage of 200 mg of CE in refracted doses were given. After 2-3 days, a single dose of 200 mg was administered. All patients were observed for 6 hours after each challenge, and controlled again after 24 hours to exclude delayed reactions. The challenge was considered positive if one or more of the following appeared: erythema, rush or urticaria-angioedema.\nRESULTS: No reaction was observed with placebo and eight patients (88.8%) tolerated CE. Only one patient developed a moderate angioedema of the lips.\nCONCLUSION: Only one hypersensitivity reaction to CE was documented among 9 P and N-highly NSAIDs intolerant patients. Thus, we conclude that CE is a reasonably safe alternative to be used in subjects who do not tolerate P and N."}

LitCoin-GeneOrGeneProduct-v3

{"project":"LitCoin-GeneOrGeneProduct-v3","denotations":[{"id":"T1","span":{"begin":556,"end":561},"obj":"GeneOrGeneProduct"},{"id":"T2","span":{"begin":1373,"end":1377},"obj":"GeneOrGeneProduct"},{"id":"T3","span":{"begin":1547,"end":1551},"obj":"GeneOrGeneProduct"}],"text":"Safety of celecoxib in patients with adverse skin reactions to acetaminophen (paracetamol) and nimesulide associated or not with common non-steroidal anti-inflammatory drugs.\nBACKGROUND: Acetaminophen (paracetamol--P) and Nimesulide (N) are widely used analgesic-antipyretic/anti-inflammatory drugs. The rate of adverse hypersensitivity reactions to these agents is generally low. On the contrary non-steroidal anti-inflammatory drugs (NSAIDs) are commonly involved in such reactions. Celecoxib (CE) is a novel drug, with high selectivity and affinity for COX-2 enzyme.\nOBJECTIVE: We evaluated the tolerability of CE in a group of patients with documented history of adverse cutaneous reactions to P and N associated or not to classic NSAIDs.\nMETHODS: We studied 9 patients with hypersensitivity to P and N with or without associated reactions to classic NSAIDs. The diagnosis of P and N-induced skin reactions was based in vivo challenge. The placebo was blindly administered at the beginning of each challenge. After three days, a cumulative dosage of 200 mg of CE in refracted doses were given. After 2-3 days, a single dose of 200 mg was administered. All patients were observed for 6 hours after each challenge, and controlled again after 24 hours to exclude delayed reactions. The challenge was considered positive if one or more of the following appeared: erythema, rush or urticaria-angioedema.\nRESULTS: No reaction was observed with placebo and eight patients (88.8%) tolerated CE. Only one patient developed a moderate angioedema of the lips.\nCONCLUSION: Only one hypersensitivity reaction to CE was documented among 9 P and N-highly NSAIDs intolerant patients. Thus, we conclude that CE is a reasonably safe alternative to be used in subjects who do not tolerate P and N."}

LitCoin_Mondo_095

{"project":"LitCoin_Mondo_095","denotations":[{"id":"T1","span":{"begin":45,"end":49},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T2","span":{"begin":320,"end":336},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3","span":{"begin":779,"end":795},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T5","span":{"begin":896,"end":900},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T6","span":{"begin":1381,"end":1390},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T7","span":{"begin":1391,"end":1401},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T8","span":{"begin":1529,"end":1539},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T9","span":{"begin":1574,"end":1599},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A8","pred":"mondo_id","subj":"T8","obj":"0010481"},{"id":"A1","pred":"mondo_id","subj":"T1","obj":"0002531"},{"id":"A5","pred":"mondo_id","subj":"T5","obj":"0002531"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"0000605"},{"id":"A9","pred":"mondo_id","subj":"T9","obj":"0000605"},{"id":"A6","pred":"mondo_id","subj":"T6","obj":"0005492"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"0005271"},{"id":"A4","pred":"mondo_id","subj":"T3","obj":"0000605"},{"id":"A7","pred":"mondo_id","subj":"T7","obj":"0010481"}],"text":"Safety of celecoxib in patients with adverse skin reactions to acetaminophen (paracetamol) and nimesulide associated or not with common non-steroidal anti-inflammatory drugs.\nBACKGROUND: Acetaminophen (paracetamol--P) and Nimesulide (N) are widely used analgesic-antipyretic/anti-inflammatory drugs. The rate of adverse hypersensitivity reactions to these agents is generally low. On the contrary non-steroidal anti-inflammatory drugs (NSAIDs) are commonly involved in such reactions. Celecoxib (CE) is a novel drug, with high selectivity and affinity for COX-2 enzyme.\nOBJECTIVE: We evaluated the tolerability of CE in a group of patients with documented history of adverse cutaneous reactions to P and N associated or not to classic NSAIDs.\nMETHODS: We studied 9 patients with hypersensitivity to P and N with or without associated reactions to classic NSAIDs. The diagnosis of P and N-induced skin reactions was based in vivo challenge. The placebo was blindly administered at the beginning of each challenge. After three days, a cumulative dosage of 200 mg of CE in refracted doses were given. After 2-3 days, a single dose of 200 mg was administered. All patients were observed for 6 hours after each challenge, and controlled again after 24 hours to exclude delayed reactions. The challenge was considered positive if one or more of the following appeared: erythema, rush or urticaria-angioedema.\nRESULTS: No reaction was observed with placebo and eight patients (88.8%) tolerated CE. Only one patient developed a moderate angioedema of the lips.\nCONCLUSION: Only one hypersensitivity reaction to CE was documented among 9 P and N-highly NSAIDs intolerant patients. Thus, we conclude that CE is a reasonably safe alternative to be used in subjects who do not tolerate P and N."}

LitCoin-MeSH-Disease-2

{"project":"LitCoin-MeSH-Disease-2","denotations":[{"id":"T1","span":{"begin":45,"end":59},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T2","span":{"begin":155,"end":167},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3","span":{"begin":280,"end":292},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T4","span":{"begin":320,"end":336},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T5","span":{"begin":416,"end":428},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T6","span":{"begin":675,"end":694},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T7","span":{"begin":779,"end":795},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T8","span":{"begin":896,"end":910},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T9","span":{"begin":1363,"end":1371},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T10","span":{"begin":1381,"end":1390},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T11","span":{"begin":1391,"end":1401},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T12","span":{"begin":1529,"end":1539},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T13","span":{"begin":1574,"end":1590},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A10","pred":"ID:","subj":"T10","obj":"D014581"},{"id":"A4","pred":"ID:","subj":"T4","obj":"D006967"},{"id":"A5","pred":"ID:","subj":"T5","obj":"DISEASE"},{"id":"A12","pred":"ID:","subj":"T12","obj":"D000799"},{"id":"A1","pred":"ID:","subj":"T1","obj":"DISEASE"},{"id":"A7","pred":"ID:","subj":"T7","obj":"D006967"},{"id":"A8","pred":"ID:","subj":"T8","obj":"DISEASE"},{"id":"A11","pred":"ID:","subj":"T11","obj":"D000799"},{"id":"A2","pred":"ID:","subj":"T2","obj":"DISEASE"},{"id":"A9","pred":"ID:","subj":"T9","obj":"D004890"},{"id":"A3","pred":"ID:","subj":"T3","obj":"DISEASE"},{"id":"A6","pred":"ID:","subj":"T6","obj":"DISEASE"},{"id":"A13","pred":"ID:","subj":"T13","obj":"D006967"}],"text":"Safety of celecoxib in patients with adverse skin reactions to acetaminophen (paracetamol) and nimesulide associated or not with common non-steroidal anti-inflammatory drugs.\nBACKGROUND: Acetaminophen (paracetamol--P) and Nimesulide (N) are widely used analgesic-antipyretic/anti-inflammatory drugs. The rate of adverse hypersensitivity reactions to these agents is generally low. On the contrary non-steroidal anti-inflammatory drugs (NSAIDs) are commonly involved in such reactions. Celecoxib (CE) is a novel drug, with high selectivity and affinity for COX-2 enzyme.\nOBJECTIVE: We evaluated the tolerability of CE in a group of patients with documented history of adverse cutaneous reactions to P and N associated or not to classic NSAIDs.\nMETHODS: We studied 9 patients with hypersensitivity to P and N with or without associated reactions to classic NSAIDs. The diagnosis of P and N-induced skin reactions was based in vivo challenge. The placebo was blindly administered at the beginning of each challenge. After three days, a cumulative dosage of 200 mg of CE in refracted doses were given. After 2-3 days, a single dose of 200 mg was administered. All patients were observed for 6 hours after each challenge, and controlled again after 24 hours to exclude delayed reactions. The challenge was considered positive if one or more of the following appeared: erythema, rush or urticaria-angioedema.\nRESULTS: No reaction was observed with placebo and eight patients (88.8%) tolerated CE. Only one patient developed a moderate angioedema of the lips.\nCONCLUSION: Only one hypersensitivity reaction to CE was documented among 9 P and N-highly NSAIDs intolerant patients. Thus, we conclude that CE is a reasonably safe alternative to be used in subjects who do not tolerate P and N."}

LitCoin-MONDO_bioort2019

{"project":"LitCoin-MONDO_bioort2019","denotations":[{"id":"T1","span":{"begin":45,"end":59},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T2","span":{"begin":320,"end":336},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3","span":{"begin":675,"end":694},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T4","span":{"begin":779,"end":795},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T5","span":{"begin":896,"end":910},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T6","span":{"begin":1363,"end":1371},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T7","span":{"begin":1381,"end":1390},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T8","span":{"begin":1391,"end":1401},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T9","span":{"begin":1529,"end":1539},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T10","span":{"begin":1574,"end":1590},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A5","pred":"#label","subj":"T5","obj":"DISEASE"},{"id":"A1","pred":"#label","subj":"T1","obj":"DISEASE"},{"id":"A8","pred":"#label","subj":"T8","obj":"D000799"},{"id":"A9","pred":"#label","subj":"T9","obj":"D000799"},{"id":"A6","pred":"#label","subj":"T6","obj":"D004890"},{"id":"A2","pred":"#label","subj":"T2","obj":"D006967"},{"id":"A4","pred":"#label","subj":"T4","obj":"D006967"},{"id":"A3","pred":"#label","subj":"T3","obj":"DISEASE"},{"id":"A7","pred":"#label","subj":"T7","obj":"D014581"},{"id":"A10","pred":"#label","subj":"T10","obj":"D006967"}],"text":"Safety of celecoxib in patients with adverse skin reactions to acetaminophen (paracetamol) and nimesulide associated or not with common non-steroidal anti-inflammatory drugs.\nBACKGROUND: Acetaminophen (paracetamol--P) and Nimesulide (N) are widely used analgesic-antipyretic/anti-inflammatory drugs. The rate of adverse hypersensitivity reactions to these agents is generally low. On the contrary non-steroidal anti-inflammatory drugs (NSAIDs) are commonly involved in such reactions. Celecoxib (CE) is a novel drug, with high selectivity and affinity for COX-2 enzyme.\nOBJECTIVE: We evaluated the tolerability of CE in a group of patients with documented history of adverse cutaneous reactions to P and N associated or not to classic NSAIDs.\nMETHODS: We studied 9 patients with hypersensitivity to P and N with or without associated reactions to classic NSAIDs. The diagnosis of P and N-induced skin reactions was based in vivo challenge. The placebo was blindly administered at the beginning of each challenge. After three days, a cumulative dosage of 200 mg of CE in refracted doses were given. After 2-3 days, a single dose of 200 mg was administered. All patients were observed for 6 hours after each challenge, and controlled again after 24 hours to exclude delayed reactions. The challenge was considered positive if one or more of the following appeared: erythema, rush or urticaria-angioedema.\nRESULTS: No reaction was observed with placebo and eight patients (88.8%) tolerated CE. Only one patient developed a moderate angioedema of the lips.\nCONCLUSION: Only one hypersensitivity reaction to CE was documented among 9 P and N-highly NSAIDs intolerant patients. Thus, we conclude that CE is a reasonably safe alternative to be used in subjects who do not tolerate P and N."}

LitCoin-Chemical-MeSH-CHEBI

LitCoin-NCBITaxon-2

{"project":"LitCoin-NCBITaxon-2","denotations":[{"id":"T1","span":{"begin":23,"end":31},"obj":"OrganismTaxon"},{"id":"T2","span":{"begin":631,"end":639},"obj":"OrganismTaxon"},{"id":"T3","span":{"begin":765,"end":773},"obj":"OrganismTaxon"},{"id":"T4","span":{"begin":1160,"end":1168},"obj":"OrganismTaxon"},{"id":"T5","span":{"begin":1460,"end":1468},"obj":"OrganismTaxon"},{"id":"T6","span":{"begin":1500,"end":1507},"obj":"OrganismTaxon"},{"id":"T7","span":{"begin":1662,"end":1670},"obj":"OrganismTaxon"}],"text":"Safety of celecoxib in patients with adverse skin reactions to acetaminophen (paracetamol) and nimesulide associated or not with common non-steroidal anti-inflammatory drugs.\nBACKGROUND: Acetaminophen (paracetamol--P) and Nimesulide (N) are widely used analgesic-antipyretic/anti-inflammatory drugs. The rate of adverse hypersensitivity reactions to these agents is generally low. On the contrary non-steroidal anti-inflammatory drugs (NSAIDs) are commonly involved in such reactions. Celecoxib (CE) is a novel drug, with high selectivity and affinity for COX-2 enzyme.\nOBJECTIVE: We evaluated the tolerability of CE in a group of patients with documented history of adverse cutaneous reactions to P and N associated or not to classic NSAIDs.\nMETHODS: We studied 9 patients with hypersensitivity to P and N with or without associated reactions to classic NSAIDs. The diagnosis of P and N-induced skin reactions was based in vivo challenge. The placebo was blindly administered at the beginning of each challenge. After three days, a cumulative dosage of 200 mg of CE in refracted doses were given. After 2-3 days, a single dose of 200 mg was administered. All patients were observed for 6 hours after each challenge, and controlled again after 24 hours to exclude delayed reactions. The challenge was considered positive if one or more of the following appeared: erythema, rush or urticaria-angioedema.\nRESULTS: No reaction was observed with placebo and eight patients (88.8%) tolerated CE. Only one patient developed a moderate angioedema of the lips.\nCONCLUSION: Only one hypersensitivity reaction to CE was documented among 9 P and N-highly NSAIDs intolerant patients. Thus, we conclude that CE is a reasonably safe alternative to be used in subjects who do not tolerate P and N."}

LitCoin-training-merged